Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionomics Limited (trading symbol: BNOX) on November 18, 2024. The registrant is an emerging growth company incorporated in Australia. The filing primarily addresses the entry into a new material definitive agreement regarding an equity offering program.
Key Financial Metrics and Capital Structure
This filing does not contain audited financial statements, revenue, profit, or cash flow data. The financial details provided relate exclusively to the terms of a new capital raising facility:
- Offering Type: At-The-Market (ATM) Offering Agreement.
- Maximum Aggregate Offering Amount: Up to $2,000,000 in American Depositary Shares (ADS).
- Sales Agent: H.C. Wainwright & Co., LLC.
- Commission: Up to 3.0% of gross proceeds from each sale.
- Legal Cost Reimbursement: Up to $50,000 for the Sales Agent's legal counsel.
Material Changes Versus Prior Period
The Company terminated its previous ATM program to initiate this new agreement:
- Previous Program: An ATM offering with Cantor Fitzgerald & Co. under a Form F-3 registration statement (File No. 333-271696) with an aggregate sale price of up to $11,500,000.
- Change: The previous agreement was terminated prior to the execution of the new agreement with H.C. Wainwright & Co., LLC.
- Current Status: The new program is subject to the effectiveness of a new shelf registration statement on Form S-3 (File No. 333-283306) filed on November 18, 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company is not obligated to make any sales under the new Sales Agreement.
- No assurance is given that any shares will be sold, nor regarding the price, amount, or timing of potential sales.
- Sales will be made in "at the market offerings" consistent with normal trading practices.
Risks and Contingencies:
- Effectiveness Requirement: No offers or sales can occur until the new Registration Statement is declared effective by the SEC.
- Termination Rights: Either the Company or the Sales Agent may suspend or terminate the offering under certain circumstances.
- Indemnification: The Company has agreed to indemnify the Sales Agent against certain liabilities, including those under the Securities Act.
Investor Verification Checklist
- Verify the effectiveness status of the new Form S-3 Registration Statement (File No. 333-283306) to confirm if sales can commence.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination triggers and covenants.
- Monitor future filings for actual sales activity, as the Company is under no obligation to sell shares.
- Confirm the impact of the 3.0% commission and up to $50,000 legal reimbursement on net proceeds if sales occur.